{"groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"FG000","title":"Blinatumomab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"STARTED"},{"achievements":[{"comment":"Indicates participants ongoing in study as of the data cut-off date of 20 May 2015.","groupId":"FG000","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Results are reported as of the data cut-off date of 20 May 2015.","recruitmentDetails":"This study was conducted at 19 centers in 4 European countries and the United States: 3 centers in France, 3 in Germany, 5 in Italy, 1 in the United Kingdom, and 7 in the United States.\n\nThe first participant enrolled on 03 January 2014 and the last participant enrolled on 12 January 2015."}